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ABSTRACT The conjugation of siderophores to antimicrobial molecules is an attrac-
tive strategy to overcome the low outer membrane permeability of Gram-negative
bacteria. In this Trojan horse approach, the transport of drug conjugates is redi-
rected via TonB-dependent receptors (TBDR), which are involved in the uptake of es-
sential nutrients, including iron. Previous reports have demonstrated the involve-
ment of the TBDRs PiuA and PirA from Pseudomonas aeruginosa and their
orthologues in Acinetobacter baumannii in the uptake of siderophore-beta-lactam
drug conjugates. By in silico screening, we further identiﬁed a PiuA orthologue,
termed PiuD, present in clinical isolates, including strain LESB58. The piuD gene in
LESB58 is located at the same genetic locus as piuA in strain PAO1. PiuD has a simi-
lar crystal structure as PiuA and is involved in the transport of the siderophore-drug
conjugates BAL30072, MC-1, and ceﬁderocol in strain LESB58. To screen for addi-
tional siderophore-drug uptake systems, we overexpressed 28 of the 34 TBDRs of
strain PAO1 and identiﬁed PfuA, OptE, OptJ, and the pyochelin receptor FptA as
novel TBDRs conferring increased susceptibility to siderophore-drug conjugates. The
existence of a TBDR repertoire in P. aeruginosa able to transport siderophore-
drug molecules potentially decreases the likelihood of resistance emergence dur-
ing therapy.
KEYWORDS Pseudomonas aeruginosa, TonB-dependent receptor, siderophore-drug
conjugate
With the shortage of novel classes of antimicrobials, alternative approaches aimingto increase antimicrobial penetration into Gram-negative bacteria have gained
widespread interest. Such approaches include the inhibition of broad-spectrum efﬂux
pumps (1), adjuvants that increase cell permeability (2), and the redirection of drug
uptake through speciﬁc nutrient transport systems (3). The most prominent example of
the latter approach is the hijacking of essential bacterial iron transport systems by
linking antimicrobial molecules to siderophores in a Trojan horse strategy. The recent
development of such compounds by all major pharmaceutical companies historically
involved in antimicrobial drug development highlights the increasing interest in this
appealing concept (4–7). So far, most of the efforts have focused on the design and
study of beta-lactam-siderophore conjugates. Since their targets are located in the
periplasmic space, the conjugates do not require further translocation across the inner
membrane. Moreover, the conjugates are designed such that the siderophore moiety
does not interfere with the drug target interaction and does not require prior cleavage
(8). The beta-lactam scaffolds used for the design of such conjugates include penicillins
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(9), cephalosporins (KP736 and ceﬁderocol) (7, 10), and monobactams (BAL30072 and
MC-1) (4, 5). The iron-binding moiety of these beta-lactam conjugates is either a
catechol-type siderophore such as dihydroxypyridone or a mixed catechol/hydroxam-
ate (11). Both the monobactam (5, 12–14) and the cephalosporin conjugates (15)
showed potent activity against the Gram-negative nonfermenters Pseudomonas aerugi-
nosa and Acinetobacter baumannii.
Two TonB-dependent receptors (TBDRs), PiuA and PirA, have been shown to be
responsible for the uptake of BAL30072, MC-1, and ceﬁderocol in P. aeruginosa (5, 16,
17). We previously observed that some P. aeruginosa isolates did not carry the piuA
gene, although they were susceptible to BAL30072 (16). Therefore, we suspected that
other TonB-dependent receptors (TBDRs) might be present in these strains or that their
expression differs with respect to the PAO1 reference strain. Furthermore, the expres-
sion of TBDRs is often regulated by sigma/anti-sigma factors or two-component
systems (18) and is induced by the presence of the corresponding siderophore (19, 20).
These receptors could potentially participate in siderophore-drug uptake, but their
contribution is masked under standard noninducing conditions. Therefore, we per-
formed an in silico screen for PiuA orthologues in the P. aeruginosa genome database,
and we additionally expressed from plasmids 28 of the 34 TBDRs of PAO1. This enabled
us to identify a novel TBDR, termed PiuD, sharing 60% amino acid identity with PiuA,
as well as ﬁve additional TBDRs of PAO1, potentially involved in the uptake of three
different siderophore-drug conjugates, including the most recent catechol-based com-
pound, ceﬁderocol (21).
RESULTS
piuD and piuA encode homologous proteins and are mutually exclusive in P.
aeruginosa genomes. We and others (5) previously identiﬁed the TonB-dependent
receptors (TBDR) PiuA and PirA as transporters for the uptake of siderophore-drug
conjugates BAL30072 and MC-1 (Fig. 1) both in P. aeruginosa (16) and in A. baumannii
(22). When performing PCR ampliﬁcations of piuA from P. aeruginosa clinical isolates, we
noticed the absence of a piuA signal in 54% of genotypically nonredundant isolates
FIG 1 Siderophore-drug conjugates used in this study. BAL30072 and MC-1 contain a dihydroxypyridone
as a siderophore, while ceﬁderocol contains a chlorinated catechol group.
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collected from intensive care unit patients (data not shown). We performed a homology
search for potential orthologues of PiuA in the genome of LESB58, a strain that we
previously showed lacks the piuA gene (16). The BLAST algorithm identiﬁed an open
reading frame (ORF) of 766 amino acids in strains LESB58 (PALES_48941) and 39016
(PA39016_000870080), showing 60% amino acid identity with PiuA of PAO1 (753 amino
acids). The highest sequence identity was observed in the N terminus (99% amino acid
identity in the ﬁrst 84 residues, including the signal sequence) and the putative
substrate binding loops (NL1 to NL3) (see Fig. S1 in the supplemental material). We
termed this PiuA orthologue PiuD. The piuD gene has a GC content of 59%, which is
below the average of 66% for P. aeruginosa. To determine whether piuD would be
present in strains from which piuA could not be ampliﬁed, we performed a multiplex
PCR with piuA and piuD primer sets on the same set of genetically distinct clinical
isolates tested above for piuA. The multiplex PCR conﬁrmed our hypothesis, showing a
PCR band either for piuA or for piuD, suggesting that both genes are mutually exclusive
in P. aeruginosa genomes (see Fig. S2A). The piuD gene was found to be embedded in
the same genomic context as piuA (16), since the gene products of piuB (PA4513)
located downstream of piuA and those of the two genes piuC (PA4515) and piuE
(PA4516), transcribed in an opposite direction, shared 98% amino acid identities with
their homologues in LESB58 (Fig. S2B).
Contribution of PiuD and PirA to the activity of siderophore-beta-lactam
conjugates. We compared the contributions of PiuA and PiuD with that of PirA,
conserved in PAO1 and LESB58, to the activity of various siderophore-drug conjugates.
To this end, we constructed deletion mutants in the piuD (PALES_48941) and pirA
(PALES_43851) genes of LESB58. We tested the monobactam drugs BAL30072 (4) and
MC-1 (5), conjugated to a hydroxypyridone siderophore, as well as the cephalosporin
derivative ceﬁderocol, linked to a catechol siderophore (7) (Fig. 1). In the PAO1
background, both types of conjugates were strongly affected by the deletion of piuA (8-
to 32-fold increase in MICs) but not by a pirA deletion. Surprisingly, the deletion of the
pirA gene in the LESB58 background showed a stronger effect on the activities of the
hydroxypyridone conjugates (8- to 16-fold increase in MICs) than on the catechol
conjugate ceﬁderocol (2-fold increase in MICs). Conversely, the deletion of piuD in-
creased ceﬁderocol MICs 32-fold, while MICs for MC-1 and BAL30072 increased by only
2- and 4-fold, respectively (Table 1). This could reﬂect the different expression levels of
these receptors and/or the different afﬁnities for the two types of siderophore-drug
conjugates.
To address this question, we extracted RNA from PAO1 and LESB58 from late
exponential-phase cells grown under the same conditions as for the MIC assays and
measured by reverse transcription-quantitative PCR (qRT-PCR) the expression of piuA
and piuD in comparison to that of pirA. As shown in Fig. 2, pirA was expressed 3-fold
less than piuA in PAO1, while the relative expression levels between pirA and piuD were
comparable in strain LESB58. The low basal expression level of pirA might therefore not
be sufﬁcient to contribute to siderophore-drug uptake in PAO1, as highlighted by the
TABLE 1 Susceptibility of piuD and pirA deletion mutants of P. aeruginosa PAO1 and
LESB58
Strain
MIC (mg/liter)a
BAL MC-1 ATM CFD CAZ
PAO1 1 0.5 4 0.5 2
PAO1ΔpiuA 8 8 4 8 2
PAO1ΔpirA 1 0.5 4 0.5 2
PAO1ΔpiuAΔpirA 16 16 4 16 2
LESB58 1 1 16 0.06 4
LESB58ΔpiuD 4 2 16 2 4
LESB58ΔpirA 16 8 16 0.125 4
LESB58ΔpiuDΔpirA 32 32 16 4 4
aMICs were determined in MHB-Chelex. BAL, BAL30072; ATM, aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
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identical MIC values of the pirA mutant and the wild-type strain PAO1 (Table 1). In
contrast, in LESB58, PirA seemed to transport preferentially the hydroxypyridones
BAL30072 and MC-1, while ceﬁderocol uptake occurred mainly via PiuD. Since PirA
amino acid sequences from PAO1 and LESB58 (PALES_43851) are 99% identical, this
difference was not due to altered substrate afﬁnities.
Crystal structure of PiuD from P. aeruginosa. We previously determined the
crystal structure of PiuA from P. aeruginosa and its orthologue from A. baumannii (22).
Here, we determined the structure of PiuD from strain 39016, which shows 99.6%
amino acid identity with PiuD (PALES_48941) from LESB58. The obtained PiuD structure
was similar to that of PiuA from PAO1. The crystallographic asymmetric unit has two
monomers (denoted A and B). PiuD comprised two domains, a 22-stranded transmem-
brane -barrel and an N-terminal plug domain (residues 27 to 156) folded inside the
barrel (Fig. 3). The plug domain has two -sheets and two -helices, which together,
occluded the central pore. As often occurs in the TBDR structures, some of the
extracellular loops were not experimentally located in the PiuD structure. In the B
monomer, these regions, namely, NL1 (83 and 84), NL3 (113 and 114), the loop 138
to 141 of the plug domain, L7 (504 to 530), L8 (564 to 572), and L9 (609 to 624), were
presumed to be disordered. The closest structural relatives were PiuA of A. bau-
mannii (root mean square deviation [RMSD] of 1.1 Å over 701 residues) and P.
FIG 2 Expression analysis of pirA and piuA in PAO1 and pirA and piuD in LESB58. RNA was extracted from
cells grown to late exponential phase in MHB. qPCR was performed using target-gene-speciﬁc primers.
Expression of pirA is 3-fold lower than piuA in a PAO1 background, while piuD and pirA expression levels
are comparable in strain LESB58. Values are the expression ratios of the target gene divided by the rpsL
housekeeping gene. The expression of piuA and piuD was set to 1 (100%) in the respective strain. Values
show the means from three independent experiments performed in duplicates. Error bars indicate
standard deviations. *, P  0.05 by Student t test; ***, P  0.001 by analysis of variance (ANOVA); ns, not
signiﬁcant.
FIG 3 Crystal structure of PiuD from P. aeruginosa. Side (A) and extracellular (B) views of PiuD. The 22-stranded
transmembrane -barrel is colored in green. -Sheets of the plug domain are colored in yellow, loops in green, and
helices in red. (C) Structural comparison between PiuA (light blue) and PiuD (green).
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aeruginosa (1.1 Å over 656 residues) and the pyochelin receptor FptA from P.
aeruginosa (1.8 Å over 655 residues) (23). As a consequence of the disorder, one side
of the extracellular -barrel was absent. A “belt” of outward facing hydrophobic
residues (Trp 445, 486, 541, and 594, Phe 157, 180, 217, 350, 648, and 731, and Tyr
645 and 685), sits at the periplasmic end of the barrel, a characteristic of outer
membrane proteins.
Proteomic analysis under Fe chelation. To identify further siderophore-drug
transporters, we reasoned that under iron-limiting conditions, the expression of Fe-
repressed TBDRs would be upregulated and could potentially contribute to the trans-
port of siderophore-drug conjugates. Therefore, we performed a proteome analysis
using PAO1 cells grown in Mueller-Hinton broth (MHB) and in MHB treated with Chelex,
which complexes ferric iron but also divalent metal cations. The TBDRs for the endog-
enous siderophores pyochelin (FptA) and pyoverdin (FpvA and FpvB) showed the
strongest induction in the Chelex-treated medium (40- to 130-fold increases) (Fig. 4).
We also observed an induction of the heme receptors PhuR and HasR, as well as of the
Zn transporter ZnuD. The expression of the known siderophore-drug transporters PiuA
and PirA increased 2- and 10-fold, respectively, upon iron chelation. Among the TBDRs
expected or reported to transport xenosiderophores, 11 showed a 2-fold increase in
expression. CirA was below the 2-fold induction threshold, and six xenosiderophore
receptors were not expressed or were expressed below the detection limit.
Constitutive expression of TonB-dependent receptors in PAO1. To assess the
possible involvement of these receptors in siderophore-drug uptake, we cloned 26 of
the 34 TBDR genes from PAO1 (see Table S1), including the Chelex-induced TBDRs
(FiuA, FemA, FoxA, OptJ, OptN, ChtA, and CirA) and those that were undetectable. We
cloned the corresponding genes into a vector harboring a constitutively expressed
promoter in P. aeruginosa and transferred the resulting plasmids into strain PAO1. We
excluded the heme/hemophore transporters (PhuR, HasR, HxuC, and OptI), the cobal-
amin transporter BtuB (PA1271), and the citrate receptor FecA. For comparison, we
included the previously identiﬁed receptor genes piuA and pirA, as well as the newly
identiﬁed piuA orthologue piuD. The susceptibility data clearly showed that six TBDRs,
namely, PiuD, OptJ, FemA, OptE, PfuA, and FptA, increased by at least 4-fold the
susceptibility of PAO1 to the three siderophore-drug conjugates tested (shown in bold
in Table 2). The strain harboring pPA0151 showed a 4-fold increase in susceptibility only
FIG 4 Proteomic analysis of TBDRs from P. aeruginosa PAO1. Protein expression levels were compared
between cells grown for 20 h in MHB or Chelex-treated MHB. The dashed line indicates the 2-fold
induction threshold level.
Siderophore-Drug Receptor Repertoire in P. aeruginosa Antimicrobial Agents and Chemotherapy
June 2018 Volume 62 Issue 6 e00097-18 aac.asm.org 5
 o
n
 June 7, 2018 by ST ANDREW
S UNIV
http://aac.asm
.org/
D
ow
nloaded from
 
for the dihydroxypyridone-containing drugs BAL30072 and MC-1, and the strain har-
boring ChtA only showed increased susceptibility for the catechol-based ceﬁderocol.
Surprisingly, the overexpression of PfuA, which was undetectable by proteome analysis,
produced the largest increase in susceptibility (32-fold for BAL30072). With the
exception of a 4-fold-decreased MIC for ceftazidime (pPA0151), we observed no
signiﬁcant changes in MICs for the nonsiderophore drugs aztreonam and ceftazidime.
Since OptJ was induced to a similar level as PirA under Chelex treatment (Fig. 4), we
constructed deletions in optJ in PAO1 and its piuA and pirA deletion mutants. As for a
pirA deletion in PAO1, optJ deletion had no effect on siderophore-drug conjugate MICs
(see Table S4). However, a consistent 2-fold increase in BAL30072 MICs in a piuA
deletion background suggests a minor contribution of OptJ under uninduced condi-
tions in a PAO1 background.
To assess whether the observed changes in susceptibility could result from indirect
effects on the expression level of the main siderophore-drug transporter PiuA, we
introduced the relevant constructs in a PAO1ΔpiuA deletion mutant and tested the
drug susceptibilities. PiuA, PirA, and PiuD expression decreased the MICs of all three
siderophore-drug conjugates by 8- to 32-fold (Table 3). Interestingly, PirA overex-
pression produced only a 4- to 8-fold MIC decrease for ceﬁderocol compared to that of
the vector control, while PiuD expression resulted in a32-fold MIC decrease (Table 3).
This ﬁnding is in agreement with the susceptibilities of pirA and piuD mutants in strain
LESB58 (Table 1), which suggested preferential transport of ceﬁderocol via PiuD. The
overexpression of PfuA showed MIC changes exceeding those conferred by PiuA and
TABLE 2 Effect of overexpression of TonB-dependent receptors on P. aeruginosa
susceptibilities to three siderophore-drug conjugates
Strain or plasmida
MIC (mg/liter)b
BAL MC-1 ATM CFD CAZ
PAO1 1 0.25 4 0.5 1
pIApX2 (vector) 1 0.25 4 0.5 1
ppiuA1.1 0.06–0.125 0.06 4 0.03–0.06 1
ppirA1.1 0.06–0.125 0.06 4 0.03–0.06 1
ppiuD 0.06–0.125 0.03 4 0.03 1
poptJ (PA0434) 0.06–0.125 0.03 4 0.03–0.06 1
pfemA (PA1910) 0.125 0.06 2 0.06 1
poptE (PA2911) 0.25 0.06 2 0.125 1
ppfuA (PA1322) 0.03 0.03 2 0.03 1
pfptA 0.125 0.06 2 0.125 0.5
pPA0151 0.25 0.06 2 0.25 0.25
pchtA (PA4675) 0.5 0.125 2 0.125 NDc
pﬁuA (PA0470) 0.5 ND 4 0.25 1
pfoxA (PA2466) 1 0.125 2 0.25 1
ppfeA (PA2688) 1 0.25 4 0.5 ND
pcirA (PA1922) 1 0.25 4 0.25–0.5 1
poptN (PA1365) 1 0.25 4 0.5 ND
poptF (PA2590) 1 ND 4 0.5 0.5
poptQ (PA2289) 1 ND 2 0.25 0.5
poptR (PA3268) 1 0.25 2 0.5 1
pznuD (PA0781) 1 ND 2 ND ND
optO (PA2335) 0.5 0.25 2 0.5 1
poptP (PA0192) 1 0.25 2 0.5 1
poptL (PA2089) 1 0.25 4 0.5 1
poptC (PA4837) 1 0.125 2 0.5 1
pPA1613 1 0.125 4 0.5 1
poptM (PA2070) 1 0.25 4 0.5 1
psppR (PA2057) 0.5 0.25 4 0.5 2
pfvbA (PA4156) 0.5 0.125 4 0.5 0.5
pfpvA 2 0.5 8 0.5 1
pfpvB 1 0.25 4 1 1
aPlasmids in boldface font conferred a 4-fold increase in susceptibility to all siderophore-drug conjugates
compared to the vector control.
aBAL, BAL30072; ATM, aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
cND, not done.
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PirA, suggesting efﬁcient siderophore-drug transport independent of PiuA. Similar
results were obtained in a piuA-pirA double mutant (data not shown). On the other
hand, FptA and OptE expression produced 2- to 8-fold decreases for MC-1 and
ceﬁderocol, and OptJ produced a decrease only for MC-1. Finally, FemA and PA0151
expression showed no signiﬁcant MIC changes in a piuA deletion mutant, suggesting an
indirect effect on PiuA expression, when overexpressed in a PAO1 wild-type strain.
To further evaluate if additional TBDRs would be involved in the uptake of
siderophore-drug conjugates, we determined the susceptibilities under iron-limited
growth conditions in MHB Chelex and in a minimal Casamino Acids medium. We
observed 2-fold decreases in MICs of BAL30072 and MC-1 in PAO1 and the pirAmutant,
and a 4- to 8-fold drop in the piuA mutant backgrounds. The increase in susceptibility
was even more pronounced for ceﬁderocol (8- to 64-fold decreases) for the strains
tested. MICs for the nonsiderophore drugs aztreonam and ceftazidime were not
affected (see Table S5). The MICs were comparable or even lower than those obtained
by the overexpression of the individual receptors from the plasmids in the piuA mutant
background (Table 3), suggesting a simultaneous expression of several TBDRs besides
PiuA and PirA for the uptake of siderophore-drug conjugates in P. aeruginosa under
iron-limited conditions.
DISCUSSION
The Trojan horse strategy has recently gained renewed interest, as illustrated by the
development of novel siderophore-beta-lactam conjugates by pharmaceutical compa-
nies (4, 12) and academic research groups (9, 24). These differ in the beta-lactam
scaffolds (penicillins, monobactams, and cephems) as well as the attached siderophore
moieties (mono-, tris-catechols and mixed catechol-hydroxamates). Initial investiga-
tions have identiﬁed two TBDR proteins, PiuA and PirA, in P. aeruginosa (5, 16) and their
orthologues in A. baumannii (22). These are the main transporters for BAL30072 and
MC-1. While the deletion of these TBDRs affected the activity of these compounds
under standard MIC determination conditions, it remained unclear whether additional
TBDRs expressed under iron deﬁciency or upon substrate-induced expression can
contribute to drug susceptibility.
We have addressed these questions by screening for orthologues of PiuA in clinical
strains and by overexpressing 28 of the 34 TBDRs from P. aeruginosa PAO1, thereby
mimicking induction under speciﬁc physiological conditions or by natural substrates.
An in silico screen identiﬁed PiuD in LESB58 and other clinical isolates as a homologue
of PiuA, sharing 60% amino acid identity. The piuD gene was located in the same
genetic environment as piuA, including the conserved intergenic promoter region (see
Fig. S2 in the supplemental material). The lower GC content of the piuD gene (59%
compared to 66% for PAO1) suggests an acquisition by horizontal gene transfer. The
TABLE 3 Effect of overexpression of TonB-dependent receptors on siderophore-drug
conjugates activities in a piuA deletion mutant of P. aeruginosa
Strain or plasmid
MIC (mg/liter)a
BAL MC-1 ATM CFD CAZ
PAO1ΔpiuA 8 2 8 8 2
pIApX2 (vector) 8 4 4 8 2
ppiuA 0.25 0.03 4 0.06 2
ppirA 0.25 0.06 4 1–2 2
ppiuD 0.125 0.03 8 0.03–0.125 2
ppfuA 0.03 0.03 4 0.03 2
pfptA 4 0.5 2 0.25 2
poptE 4 0.5 4 2 2
poptJ 4 1 4 4–8 2
pfemA 8 2 4 8 2
pPA0151 8 4 2 8 1
aMIC changes of 4-fold compared to the vector control are shown in boldface font. BAL, BAL30072; ATM,
aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
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natural substrates of PiuA and PiuD are unknown, but the presence of conserved genes
within the piu locus, including the oxidoreductase genes piuC and piuB and the ORF
PA4516 (piuE), suggests that the metabolic fates of the natural substrates of these
receptors are similar.
The amino acid similarity between PiuA and PiuD (Fig. S1) results in very similar
crystal structures (Fig. 3). Like PiuA, PiuD also has a distinctive cluster of aromatic and
positively charged residues located inside the pore at the extracellular face (see Fig. S3).
This cluster is formed by Trp residues 311 and 327, Tyr 309, 710, and 714, Phe 94 (from
the plug domain), His 713, and Arg 329 and 333 (Fig. S3). In PiuA, Trp 239, Tyr 307, 325,
and 697, Phe 94, His 700, Lys 329, and Arg 331 form a cluster in the same position (Fig.
S3). In the pyoverdin (FpvA) and pyochelin (FptA) receptors, this cluster is directly
involved in the recognition of siderophores (23, 25). So far, there is no cocrystal
structure available for a TBDR with its siderophore-drug conjugate, and only two
cocomplexes between natural siderophores and their corresponding receptors have
been solved (26–28). However, several binding and mutation studies regarding sidero-
phore receptors and their cognate substrates have been reported (29–31), and their
results are compatible with biphasic binding kinetics involving an initial binding in the
loop extremities and a secondary binding at a site deeper inside the barrel, leading
eventually to substrate translocation.
Our proteomic analysis revealed that divalent metal cation chelation induced the
expression of 18 of the 34 TBDRs in PAO1. These include receptors for the endogenous
siderophores pyoverdin (FpvA and FpvB), pyochelin (FptA), and nicotianamine (OptC)
(32), as well as the heme (PhuR and HasR) and zinc (ZnuD) transporters. The other
induced receptors could transport xenosiderophores that P. aeruginosa may encounter
in the environment or during polymicrobial infections. A subset of these likely requires
the cognate siderophore as an inducer. One example is PfeA from PAO1, sensing the
presence of the exogenous siderophore enterobactin from Escherichia coli via the
two-component system PfeR-PfeS (33). Similarly, the siderophore mycobactin from
Mycobacterium smegmatis induces by 30-fold the expression of FemA in P. aeruginosa
(19). Strikingly, the overexpression of PfuA resulted in the largest increase in suscep-
tibility to all three siderophore-drug conjugates tested. The closest homologues of PfuA
turned out to be PiuA in PAO1 and PiuD in LESB58, both sharing a 39% amino acid
identity (57% similarity). The natural substrate of PfuA is unknown. A Fur binding site
precedes the pfuA gene (34), suggesting iron repression; however, additional regulators
and the presence of the substrate are likely required for induction of this TBDR in PAO1.
Its closest orthologue in E. coli is Fiu, a TBDR also involved in the transport of BAL30072
(our unpublished data). Other receptors, undetectable by mass spectrometry (MS)
analysis, may respond to other organic compounds or metal ions. Importantly, we
identiﬁed the pyochelin receptor FptA as a candidate for the uptake of siderophore-
drug conjugates. This receptor is the most highly induced receptor under iron limita-
tion, as highlighted by our proteome analysis. FptA is also strongly expressed in lung
and blood samples from mice and rats infected with P. aeruginosa and in human urine
and respiratory samples (D. Bumann, unpublished results). The identiﬁcation of the
natural substrates of xenosiderophore receptors, as for instance PfuA, should provide
an elegant way to induce speciﬁcally the expression of a receptor for the uptake of
siderophore-drug conjugates. It also remains to be determined if siderophore-drug
conjugates can act as inducers of their own transport, although this would require
conjugate analogues deprived of antibiotic activity. The increased susceptibility to all
three siderophore-drug conjugates under iron-limited conditions supports our ﬁndings
on the plasmid-mediated expression of the individual TBDRs.
In summary, we have provided evidence for an overlapping subset of TBDRs in P.
aeruginosa able to transport three different siderophore-drug conjugates, presenting
two different types of iron-complexing substituents and on the basis of two classes of
beta-lactams. The redundancy of TBDR recognition proﬁles should be an advantage
during therapeutic treatments, since it should limit the risk of resistance emergence to
these novel drug conjugates.
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MATERIALS AND METHODS
Bacterial strains and growth conditions. The strains and plasmids used in this study are listed in
Table S1 in the supplemental material. E. coli and P. aeruginosa were grown in lysogeny broth (LB) at 37°C
with shaking (250 rpm). E. coli DH10B was used as the cloning host and E. coli SM10 as the donor for
biparental matings. Gentamicin (15 g/ml for E. coli and 50 g/ml for P. aeruginosa) or carbenicillin (200
g/ml) was added for plasmid -carrying strains. MICs were determined in Mueller-Hinton broth (MHB)
according to CLSI guidelines (35) and were repeated at least on three different occasions. Cation-
depleted MHB was prepared by dissolving 11 g of Chelex (C7901; Sigma-Aldrich) in 100 ml MHB. After
stirring for 6 h, the suspension was ﬁltered and the ﬁltrate autoclaved at 115°C for 15 min. The
Chelex-treated MHB was supplemented with 2 mM MgSO4 and 0.2 mM CaCl2 (ﬁnal concentrations). The
M9 Casamino Acids medium contained 1 M9 salts, supplemented with 0.5% Casamino Acids (ﬁlter
sterilized), and 2 mM MgSO4.
PCR ampliﬁcations and DNA modiﬁcations. PCR primers are listed in Table S2. All primer se-
quences were based on the sequences from the pseudomonas.com website (36). For screening PCRs,
bacterial cells were boiled at 95°C for 5 min and subsequently pelleted at 13,000 rpm for 1 min. Phusion
DNA polymerase (Thermo Scientiﬁc) was used for high-ﬁdelity PCRs (supplemented with 5% dimethyl
sulfoxide [DMSO]). Restriction digestions were performed according to the manufacturer’s instructions at
the appropriate temperature. All ligation reactions were carried out at room temperature using T4 DNA
ligase (Promega). DNA preparations were performed using the GeneJET PCR puriﬁcation or the GeneJET
gel extraction kit (Thermo Scientiﬁc).
Construction of knockout mutants. The generation of unmarked knockout mutants was based on
the protocol described by Hoang et al. (37). Brieﬂy, DNA fragments of 500 to 700 bp were PCR-ampliﬁed
using primer pairs A1/A2 and B1/B2, respectively. For the deletion of pirA in strain LESB58, the up- and
downstream regions ﬂanking the gene were PCR ampliﬁed. For the knockout of piuD in strain LESB58,
the ampliﬁed fragments were located in the 5= and 3= regions of the genes. After ampliﬁcation, the
obtained A and B fragments were gel puriﬁed, and approximately 40 ng of each fragment was used in
a PCR fusion ampliﬁcation with primers A1 and B2, which share an 18-bp homologous region. The
resulting fusion products were gel puriﬁed and further cloned into the suicide vectors pEX18Gm via
HindIII/EcoRI restriction sites (pirA) and pEX18Gm via SalI/EcoRI (piuD). The cloned knockout fragments
were veriﬁed by sequencing. The replacement vectors were mobilized into P. aeruginosa via biparental
conjugation, and the generation of the unmarked mutants was carried out as previously described (38).
The deﬁned gene knockouts were veriﬁed by PCR ampliﬁcation using the external primers and subse-
quent Sanger sequencing.
Construction of expression plasmids. The coding regions, including at least 50 nucleotides (nt)
upstream of the ATG initiation codon and 20 nt downstream of the STOP codon, were ampliﬁed by PCR
from genomic DNA of P. aeruginosa 39016 (piuD) or PAO1. The piuD coding region was ampliﬁed with
primers piuD-Xba and piuD-Hind and cloned as a 2,526-bp XbaI-HindIII DNA fragment into the expres-
sion vector pIApX2, yielding plasmid ppiuD. All other constructs were prepared in a similar way using the
primers shown in Table S2. The Q5 high-ﬁdelity DNA polymerase (NEB) was used for all ampliﬁcations.
PCR conditions were as follows: denaturation at 98°C for 2 min, followed by 27 cycles of 98°C for 20 s,
57°C for 30 s, and 72°C for 2 min, and a ﬁnal extension at 72°C for 4 min. The plasmids were transferred
into P. aeruginosa by electroporation, and cells were spread on LB agar supplemented with carbenicillin
at 200 mg/liter. All constructs were veriﬁed by Sanger sequencing.
Quantitative real-time PCR. Overnight cultures of strains grown in LB were diluted and inoculated
into fresh MHB and grown in microtiter plates (200 l/well) until reaching late exponential phase. Three
wells were combined to form one sample. RNA was extracted using the RNeasy kit (Qiagen, Germany),
according to the manufacturer’s protocol. Residual genomic DNA was removed by treatment with
RNase-free DNase (Promega). One microgram of RNA was reverse transcribed using ImProm-II reverse
transcriptase (Promega). Gene-speciﬁc primers were used for PCRs using the Rotor-Gene SYBR green PCR
kit (Qiagen). qPCRs were performed in a Rotor-Gene 3000 (Corbett Research, Australia) using the
following conditions: 2 min at 95°C, followed by 35 cycles of 20 s at 95°C, 30 s at 60°C, and 30 s at 72°C,
followed by a ﬁnal extension at 72°C for 3 min. The ribosomal rpsL gene was used as a housekeeping
reference gene (39).
Cloning, overexpression, and puriﬁcation of PiuD from P. aeruginosa. The signal peptide of the
proteins was predicted with Signal P4.0 (40) and excluded from cloning. The coding sequence of the
mature protein was ampliﬁed from the genomic P. aeruginosa strain 39016 using KOD DNA polymerase
(Novagen) and the primers piuD-39016-F and piuD-39016-R. The PCR product was digested by BspHI and
XhoI restriction enzymes and cloned into the pTAMACHis6 vector using restriction sites NcoI and XhoI.
The construct results in an expressed protein with an N-terminal TamA signal sequence for the outer
membrane localization and a noncleavable C-terminal His6 tag. The pTAMACHis6 expression vector was
obtained by replacing the PelB signal peptide of pEPELBCHIS (courtesy of Huanting Liu, University St
Andrews) with the TamA signal peptide (41). PiuD was overexpressed in E. coli C43(DE3) cells. The
expression and puriﬁcation steps were as described for PiuA (22). The fractions were pooled and loaded
on a Superdex S200 gel ﬁltration column (GE Healthcare) equilibrated with 10 mM Tris (pH 8), 150 mM
NaCl, and 0.45% (vol/vol) tetraethylene glycol monooctyl ether (C8E4). Protein fractions were pooled and
concentrated to 10 mg/ml.
Crystallization and structure determination. Crystals of PiuD appeared at 20°C after a few days by
mixing 2 l of protein solution (10 mg/ml) with 1 l of reservoir solution containing 14% poly(ethylene
glycol) methyl ether (PEG MME 5000) and 0.1 M bicine (pH 9). Crystals were frozen with the same solution
containing 35% PEG MME 5000. The data were collected at ID23-1 at the ESRF. The data were processed
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with GrenADES (42–46). The structure of PiuD was solved by molecular replacement using P. aeruginosa
PiuA coordinates (PDB code 5FOK) as a model, with the program PHASER (47). The models were adjusted
with Coot (48), and the reﬁnement was carried out using REFMAC in the CCP4 program suite with TLS
parameters (49). The quality of all structures was checked with MolProbity (50). The ﬁgures were drawn
using PyMOL (version 1.8; Schrödinger, LLC). The ﬁnal reﬁnement statistics are given in Table S3.
Proteomics analysis. Sample preparation and MS analysis were performed as described previously
(33). Brieﬂy, P. aeruginosa was grown in MHB or MHB treated with Chelex (Sigma-Aldrich, Switzerland)
under standard MIC determination conditions in microtiter plates without shaking at 37°C for 18 h. The
cells from three wells were combined to yield sufﬁcient material for proteome analysis. Three replicate
samples were lysed, and the proteins were reduced with 5 mM Tris (2-carboxyethyl) phosphine
hydrochloride and alkylated with iodoacetamide. The samples were diluted before digestion with trypsin
at 37°C overnight. The peptides were desalted on a C18 reversed-phase column and dried under vacuum.
One microgram of peptide was injected into a liquid chromatography-mass spectrometer (LTQ-Orbitrap
Elite). The peptides were separated using an EASY nLC-1000 system (Thermo Fisher scientiﬁc) using a C18
high-performance liquid chromatography (LC) column. Tandem mass spectrometry data were exported
from Progenesis LC-MS and searched against a protein decoy database of P. aeruginosa.
Statistics. Data were analyzed and plotted using GraphPad Prism (ver 7.02).
Accession number(s). Atomic coordinates and structure factors for PiuD have been deposited in the
Protein Data Bank (accession no. 5NEC).
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